Skip to main content
Fig. 1 | BMC Medical Genomics

Fig. 1

From: Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine

Fig. 1

Treatment timeline for the presented patient. The patient’s initial chemotherapy regimen was gemcitabine and cisplatin (GP). After resistance to GP regimen, informed by the results of genetic tests, pazopanib was used as second-line treatment. Abdominal computer tomography showed significantly shrunk tumor size (middle image), and the patient acquired 10 months PFS. Pazopanib naïve tumor tissue were performed for both ultra-deep sequencing and WES, while tumor tissue after pazopanib resistance were performed for WES. Post-pazopanib resistant tissue also were used for PDX model

Back to article page